Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. - Wikidata - awgldk - TriplyDB

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.

http://www.wikidata.org/entity/Q36599869

about

Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.Durability of response to dapagliflozin: a review of long-term efficacy and safety.Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis.Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.The effect of dapagliflozin treatment on epicardial adipose tissue volume.Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).SGLT2 inhibitors: are they safe?Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.Pharmacological management of type 2 diabetes: what's new in 2017?Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.Un-sweetening the Heart: Possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects.

P2860

Q26746659-019C3DF5-6987-4528-8FB4-5C240DC759F6 Q28075848-5A1B8667-1BB5-4394-B51D-73467F6A5E1E Q28553482-10CAC9C6-76EE-4998-BE30-3794D538F917 Q30238791-C547D077-1AE1-4409-A5C0-8CC49CF57086 Q31112303-3B9DE593-3076-47D2-ADB9-57CC7937DC8D Q33166813-E459C5B1-A0F7-4CD9-80C9-F06757B7A1E3 Q33696974-F07D63B5-5EC8-42D3-9917-CDAC6F2F2988 Q33815573-C90768A1-3DB5-48D0-BF83-8B2A2742E98A Q33882438-82737D4D-1AF4-46EA-8DCC-688E58D97943 Q37075620-E86EF519-F27D-4CA9-A34E-BADA3204F245 Q37586607-9A8122F0-4E7F-40E5-BA31-1812F4B34036 Q37594479-8251CF9B-11FC-4D39-8F86-2AEC0EF35BCB Q37620904-BF3038C8-D715-42DB-A292-450FA3E34A0D Q37668253-5DCCB8FF-B312-4095-972F-AD64F6B5B980 Q38645792-7278EF19-D565-485A-A593-678BFE71B68D Q38783203-526CA6FC-9D7B-4A8D-91AB-0D61B0C31CC3 Q38856808-6CECEB45-AFD6-4FC9-8BFF-ADBE4074EAB8 Q38903825-95BD8E40-258C-4073-B7A7-B410C248B813 Q39013664-BC9E1B48-253C-4B55-AA80-FC74A863D93C Q39023661-5C6AADE0-4800-4CA6-A60E-8F60DADBF712 Q39126658-7E324807-9520-44F8-8397-A64EA755EB43 Q39170860-2194D3C4-87A2-4D80-A86B-30EB31E6E215 Q39189383-BBB5612B-88D5-4672-BBA9-385B27F94FBA Q39255963-C407BE85-3C11-4492-A663-E4C9928A530C Q39420208-BFBEEB72-F662-4F54-B6F9-C9EAF653F7C8 Q39430445-9B7B11D2-C313-49E1-A13D-E7AE5342B0FF Q39892657-DEA01F44-034B-4CBB-8DC7-4C9565152C8D Q40106543-9CE5BC43-F17F-4821-9174-88920BFCE5E6 Q41176211-CC6DE276-CBB8-4841-89E9-9E20CA43312B Q41551599-110FA672-DFE1-4FC1-8742-C4B2C7FACF7B Q42643753-F46C6DF5-1470-4B4B-9ED9-25E01F01592F Q47117670-85DF6248-05D7-401A-A830-C050ED4F6364 Q47137994-064186EB-597D-4AF8-9DF7-38A091F79AF1 Q47142556-06EABC57-3882-4375-8C26-05F9A3404604 Q47149127-B960A66C-D8A5-4CD6-9005-5F181EB36C03 Q47642298-75A21108-539E-43D0-9A2B-09E9A5071554 Q47687852-99375FF5-0DEC-4440-BF0B-A24F25D7E0E2 Q47696671-DABA038C-E064-4799-B73A-29213D34EC2B Q48296619-74B36FDF-DFF0-4CBA-980D-F914A74F7A43 Q49550551-00379B80-D539-4A80-9049-36012140BBCA

P2860

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.

http://www.wikidata.org/entity/Q36599869

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cardiovascular effects of dapa ...... k categories: a meta-analysis.

@ast

Cardiovascular effects of dapa ...... k categories: a meta-analysis.

@en

type

label

Cardiovascular effects of dapa ...... k categories: a meta-analysis.

@ast

Cardiovascular effects of dapa ...... k categories: a meta-analysis.

@en

prefLabel

Cardiovascular effects of dapa ...... k categories: a meta-analysis.

@ast

Cardiovascular effects of dapa ...... k categories: a meta-analysis.

@en

P1433

Q36599869-ECA795B4-2258-4DB1-A4C7-328C7179ADE9

P1476

Q36599869-1E930BBC-1201-4FA5-8FE3-61C159869A9B

P2093

Q36599869-1DB8331E-DEE7-4535-9F40-96B0020C3B97

Q36599869-5B9CCE18-9D19-4861-97AE-3B585A80AEB9

Q36599869-8639DC84-E37D-44ED-A56D-38BE27DA07BB

Q36599869-C119E421-CA42-4453-9919-6BA880BD67F1

P2860

Q36599869-019478E9-33E4-493E-B75C-46D42FA24C6F

Q36599869-03846470-F0A5-4431-85A3-E6E8A7D0A058

Q36599869-09768FA9-9130-4FF1-BA02-3C0840F326EF

Q36599869-0A31DFB8-01C9-4AA5-AF72-EEC7B55DF4A7

Q36599869-10F859AF-0086-4B29-9C18-72E85C834CA2

Q36599869-11B3DB94-28FA-4B14-ABEF-9D6373D565FB

Q36599869-12B4CCB5-BF33-415D-8B5B-4172927A1634

Q36599869-16BD145E-6DAB-405F-8C56-37398325880D

Q36599869-198B4652-3C7A-45AD-A965-F9684BE200C7

Q36599869-2758FFA3-4EB7-4AD9-B51A-8A7BDC700A44

P2888

Q36599869-AF161C52-8CF9-4C36-90F9-50C92AB4CC02

P304

Q36599869-92AA925B-716E-4107-B3CD-2DD1798D04A0

P31

Q36599869-3F711630-ABA3-411F-A01C-70318AAA9F82

Q36599869-cdfc1f6f-290f-4298-9dd9-742693a5fe8f

P356

Q36599869-838A7140-BDF4-4CFC-9A3A-49CF9699E001

P407

Q36599869-E88084BE-7D56-497E-8F6B-111DAF7E68EA

P478

Q36599869-A4B217FF-68FC-479E-894A-B887A5653693

P577

Q36599869-C7062F30-9DF8-4838-8271-F8712DB638DD

P5875

Q36599869-AF07AA71-13DC-499B-870F-13CA69278BDC

P6179

Q36599869-DB84F086-6133-49F2-B1A7-69146A14BAC2

P698

Q36599869-B0119092-D5A9-439D-AB93-5486833B0BA8

P921

Q36599869-8C7A3781-C296-454E-9B93-4979871FF088

P932

Q36599869-92750135-341D-4280-87EE-58E8A838F9E7

P356

S12933-016-0356-Y

P1433

Cardiovascular Diabetology

P1476

Cardiovascular effects of dapa ...... k categories: a meta-analysis.

@en

P2093

Christian Sonesson

http://www.w3.org/2001/XMLSchema#string

Eva Johnsson

http://www.w3.org/2001/XMLSchema#string

Ingrid Gause-Nilsson

http://www.w3.org/2001/XMLSchema#string

Peter A Johansson

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

Glucose control and vascular complications in veterans with type 2 diabetes

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

P2888

s12933-016-0356-y

P304

37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12933-016-0356-Y

http://www.w3.org/2001/XMLSchema#string

P407

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

295246551

http://www.w3.org/2001/XMLSchema#string

P6179

1053390135

http://www.w3.org/2001/XMLSchema#string

P698

26895767

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4761166

http://www.w3.org/2001/XMLSchema#string